cancer immunotherapy, combination chemo-/immunotherapy
Showing 1 - 25 of >10,000
Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Carcinoma Trial in Aurora (Nab-paclitaxel,
Withdrawn
- Triple Negative Breast Cancer
- +4 more
- Nab-paclitaxel
- +3 more
-
Aurora, ColoradoUniversity of Colorado Hospital
Dec 2, 2022
Pleural Mesothelioma Trial in Italy (Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab)
Not yet recruiting
- Pleural Mesothelioma
- Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab
-
Rozzano, MI, Italy
- +5 more
Nov 30, 2023
Ependymoma, Medulloblastoma, Glioblastoma Trial in Augusta (Ibrutinib, Indoximod, Cyclophosphamide)
Recruiting
- Ependymoma
- +3 more
- Ibrutinib
- +3 more
-
Augusta, GeorgiaAugusta University, Georgia Cancer Center
Dec 16, 2022
Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemo)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Split-course hypo-CCRT
- +2 more
-
Guangzhou, Guangdong, ChinaSun yat-sen University Cancer Center
Aug 26, 2023
Pancreatic Cancer Trial in Sydney, Wollongong, Melbourne (Durvalumab, Oxaliplatin, Irinotecan)
Recruiting
- Pancreatic Cancer
- Durvalumab
- +5 more
-
Sydney, New South Wales, Australia
- +2 more
Oct 19, 2023
Merkel Cell Carcinoma Trial in Milan (Retifanlimab, Cisplatin, Etoposide)
Recruiting
- Merkel Cell Carcinoma
- Retifanlimab
- +2 more
-
Milan, ItalyFondazione IRCCS Istituto Nazionale dei Tumori di Milano
Jan 4, 2023
Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant
Not yet recruiting
- Breast Cancer Triple Negative
- +3 more
-
Atlanta, GeorgiaEmory University/Winship Cancer Institute
May 18, 2023
Lung Cancer, Non-small Cell Trial in Nanjing (hypofractionated radiation therapy)
Active, not recruiting
- Lung Cancer, Non-small Cell
- hypofractionated radiation therapy
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Hospital
Mar 13, 2023
Cervical Cancer = FIGO IIB and or Lymph Node Metastases Trial (Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab),
Not yet recruiting
- Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases
- Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab)
- +2 more
- (no location specified)
Aug 16, 2022
NSCLC Stage III Trial in Shanghai (standar thoracic RT dose, decreased thoracic RT dose)
Recruiting
- Non-small Cell Lung Cancer Stage III
- standar thoracic RT dose
- decreased thoracic RT dose
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai jiaotong univestigy school of medicine
Sep 27, 2022
Small-cell Lung Cancer Trial in Shanghai (thoracic radiotherapy)
Recruiting
- Small-cell Lung Cancer
- thoracic radiotherapy
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai jiaotong univestigy school of medicine
Sep 21, 2022
Triple Negative Breast Tumors Trial (Pembrolizumab injection, Capecitabine tablets, Local radiotherapy)
Not yet recruiting
- Triple Negative Breast Neoplasms
- Pembrolizumab injection
- +2 more
- (no location specified)
Jul 25, 2023
NSCLC Trial in Guangzhou (Hypofractionated radiotherapy, induction chemo-immunotherapy, concurrent chemo)
Recruiting
- Non-small Cell Lung Cancer
- Hypofractionated radiotherapy
- +4 more
-
Guangzhou, Guangdong, ChinaSun yat-sen university cancer center
Nov 14, 2023
Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)
Active, not recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +5 more
- Atezolizumab
- +9 more
-
Duarte, California
- +3 more
Nov 17, 2022
Head Neck Cancer, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma Trial in Winston-Salem (Pembrolizumab,
Recruiting
- Head Neck Cancer
- +5 more
- Pembrolizumab
- +2 more
-
Winston-Salem, North CarolinaWake Forest Baptist Health Sciences
Aug 8, 2022
Extensive Stage Small Cell Lung Cancer Trial in Chicago, Indianapolis, Iowa City (Cisplatin, Carboplatin, Etoposide)
Recruiting
- Extensive Stage Small Cell Lung Cancer
- Cisplatin
- +4 more
-
Chicago, Illinois
- +2 more
Jul 1, 2022
Bladder Cancer Trial in Switzerland (Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC), Atezolizumab, Cisplatin)
Recruiting
- Bladder Cancer
- Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)
- +3 more
-
Baden, Switzerland
- +9 more
Aug 12, 2022
NSCLC Metastatic Trial in Salt Lake City (Durvalumab, Pemetrexed, Carboplatin)
Recruiting
- Non-Small Cell Lung Cancer Metastatic
- Durvalumab
- +2 more
-
Salt Lake City, UtahHuntsman Cancer Institute at University of Utah
Mar 1, 2022
Advanced Renal Cell Carcinoma Trial (Botensilimab, Balstilimab, Ipilimumab)
Not yet recruiting
- Advanced Renal Cell Carcinoma
- Botensilimab
- +3 more
- (no location specified)
Jun 23, 2023
Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer Trial in Newport Beach, Orlando (GL-ONC1 alone, or in
Completed
- Ovarian Cancer
- +2 more
- GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
-
Newport Beach, California
- +1 more
Jan 3, 2023
Breast Carcinoma Trial in Houston (biological, drug, other)
Not yet recruiting
- Breast Carcinoma
- eftilagimod alpha
- +2 more
-
Houston, TexasOncology Consultants
Feb 17, 2023
Colorectal Tumors Trial in New York (Botensilimab, Balstilimab)
Not yet recruiting
- Colorectal Neoplasms
-
New York, New YorkWeill Cornell Medicine/NewYork-Presbyterian Hospital
Jan 24, 2023
Small Cell Lung Carcinoma Trial in Milano (Cyclic, 5-day calorie restriction, Atezolizumab)
Not yet recruiting
- Small Cell Lung Carcinoma
- Cyclic, 5-day calorie restriction
- Atezolizumab
-
Milano, ItalyFondazione IRCCS Istituto Nazionale Tumori
Jan 19, 2023
TNBC - Triple-Negative Breast Cancer, Breast Cancer Trial (Pembrolizumab, Radiation Therapy, Axatilimab)
Not yet recruiting
- TNBC - Triple-Negative Breast Cancer
- Breast Cancer
- Pembrolizumab
- +2 more
- (no location specified)
Aug 4, 2022